Sympathoexcitation associated with renin-angiotensin system in metabolic syndrome

International Journal of Hypertension

Volumn 2013, Issue , 2013, Pages

  Kishi, Takuya ^a   Hirooka, Yoshitaka ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN INHIBITOR; ROSIGLITAZONE; TELMISARTAN;

ADRENERGIC ACTIVITY; ADRENERGIC SYSTEM; ANTIHYPERTENSIVE ACTIVITY; BLOOD BRAIN BARRIER; DIETARY INTAKE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MECHANISM; DRUG PENETRATION; DRUG TARGETING; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 84874893269     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.1155/2013/406897     Document Type: Review

References (91)

1. Grundy S. M., Cleeman J. I., Daniels S. R., Donato K. A., Eckel R. H., Franklin B. A., Gordon D. J., Krauss R. M., Savage P. J., Smith S. C., Spertus J. A., Costa F., Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005 112 17 2735 2752 2-s2.0-27444443876 10.1161/CIRCULATIONAHA.105.169404 (Pubitemid 41532612)
2. Grundy S. M., Metabolic syndrome pandemic. Arteriosclerosis, Thrombosis, and Vascular Biology 2008 28 629 636 (Pubitemid 351651324)
3. Sarzani R., Salvi F., Dessì-Fulgheri P., Rappelli A., Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. Journal of Hypertension 2008 26 5 831 843 2-s2.0-42149112825 10.1097/HJH.0b013e3282f624a0 (Pubitemid 351540757)
4. de Kloet A. D., Krause E. G., Woods S. C., The renin angiotensin system and the metabolic syndrome. Physiology and Behavior 2010 100 5 525 534 2-s2.0-77953713390 10.1016/j.physbeh.2010.03.018
5. Putnam K., Shoemaker R., Yiannikouris F., Cassia L. A., The renin-angiotensin system: a target of and contributor to dyslipidemias, altered glucose homeostasis, and hypertension of the metabolic syndrome. American Journal of Physiology 2012 302 H1219 H1230
6. Kalupahana N. S., Moustaid-Moussa N., The renin-angiotensin system: a link between obesity, inflammation and insulin resistance. Obesity Reviews 2012 13 136 149
7. Elliott W. J., Meyer P. M., Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. The Lancet 2007 369 9557 201 207 2-s2.0-33846294746 10.1016/S0140-6736(07)60108-1 (Pubitemid 46111014)
8. Kamari Y., Harari A., Shaish A., Peleg E., Sharabi Y., Harats D., Grossman E., Effect of telmisartan, angiotensin II receptor antagonist, on metabolic profile in fructose-induced hypertensive, hyperinsulinemic, hyperlipidemic rats. Hypertension Research 2008 31 1 135 140 2-s2.0-40149085377 10.1291/hypres.31.135 (Pubitemid 351325625)
9. Ogihara T., Kikuchi K., Matsuoka H., The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH, 2009). Hypertension Research 2009 32 3 107
10. Landsberg L., Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). Journal of Hypertension 2001 19 3 523 528 2-s2.0-0035066361 10.1097/00004872-200103001-00001 (Pubitemid 32280942)
11. Raumouni K., Correla M. L., Haynes W. G., Mark A. L., Obesity associated hypertension: new insights into mechanisms. Hypertension 2005 45 9 14 (Pubitemid 40066405)
12. Esler M., Straznicky N., Eikelis N., Masuo K., Lambert G., Lambert E., Mechanisms of sympathetic activation in obesity-related hypertension. Hypertension 2006 48 5 787 796 2-s2.0-33750281024 10.1161/01.HYP.0000242642. 42177.49 (Pubitemid 44610980)
13. Grassi G., Sympathetic overdrive and cardiovascular risk in the metabolic syndrome. Hypertension Research 2006 29 11 839 847 2-s2.0-33846108745 10.1291/hypres.29.839 (Pubitemid 46062115)
14. Grassi G., Adrenergic overdrive as the link among hypertension, obesity, and impaired thermogenesis: lights and shadows. Hypertension 2007 49 1 5 6 2-s2.0-33847683315 10.1161/01.HYP.0000251688.60327.37 (Pubitemid 46360327)
15. Grassi G., Arenare F., Quarti-Trevano F., Seravalle G., Mancia G., Heart rate, sympathetic cardiovascular influences, and the metabolic syndrome. Progress in Cardiovascular Diseases 2009 52 1 31 37 2-s2.0-67650178028 10.1016/j.pcad.2009.05.007
16. Matsukawa T., Gotoh E., Minamisawa K., Kihara M., Ueda S. I., Shionoiri H., Ishii M., Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. American Journal of Physiology 1991 261 3 R690 R696 2-s2.0-0025942184
17. Zera T., Ufnal M., Szczepanska-Sadowska E., Central TNF- α elevates blood pressure and sensitizes to central pressor action of angiotensin II in the infarcted rats. The Journal of Physiology and Pharmacology 2008 59 8 117 121 2-s2.0-63649109274
18. Zimmerman M. C., Lazartigues E., Lang J. A., Sinnayah P., Ahmad I. M., Spitz D. R., Davisson R. L., Superoxide mediates the actions of angiotensin II in the central nervous system. Circulation Research 2002 91 11 1038 1045 2-s2.0-0037195696 10.1161/01.RES.0000043501.47934.FA (Pubitemid 35416641)
19. Zimmerman M. C., Lazartigues E., Sharma R. V., Davisson R. L., Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circulation Research 2004 95 2 210 216 2-s2.0-3343005248 10.1161/01.RES.0000135483.12297.e4 (Pubitemid 38988688)
20. Nozoe M., Hirooka Y., Koga Y., Araki S., Konno S., Kishi T., Ide T., Sunagawa K., Mitochondria-derived reactive oxygen species mediate sympathoexcitation induced by angiotensin II in the rostral ventrolateral medulla. Journal of Hypertension 2008 26 11 2176 2184 2-s2.0-56049119631 10.1097/HJH.0b013e32830dd5d3
21. Kishi T., Hirooka Y., Konno S., Ogawa K., Sunagawa K., Angiotensin II type 1 receptor-activated caspase-3 through ras/mitogen-activated protein kinase/extracellular signal-regulated kinase in the rostral ventrolateral medulla is involved in sympathoexcitation in stroke-prone spontaneously hypertensive rats. Hypertension 2010 55 2 291 297 2-s2.0-74949083018 10.1161/HYPERTENSIONAHA.109.138636
22. Hirooka Y., Sagara Y., Kishi T., Sunagawa K., Oxidative stress and central cardiovascular regulation-pathogenesis of hypertension and therapeutic aspects. Circulation Journal 2010 74 5 827 835 2-s2.0-77951760596 10.1253/circj.CJ-10-0153
23. Kishi T., Hirooka Y., Sunagawa K., Sympathoinhibition caused by orally administered telmisartan through blockade of AT1 receptor in rostral ventrolateral medulla of hypertensive rats. Hypertension Research 2012 35 940 946
24. Konno S., Hirooka Y., Kishi T., Sunagawa K., Sympathoinhibitory effects of telmisartan through the reduction of oxidative stress in the rostral ventrolateral medulla of obesity-induced hypertensive rats. Journal of Hypertension 2012 30 1992 1999
25. Grassi G., Dell'Oro R., Quarti-Trevano F., Neuroadrenergic andreflex abnormalities in patients with metabolic syndrome. Diabetologia 2005 48 1359 1365 (Pubitemid 41186102)
26. Mancia G., Bousquet P., Elghozi J. L., Esler M., Grassi G., Julius S., Reid J., Van Zwieten P. A., The sympathetic nervous system and the metabolic syndrome. Journal of Hypertension 2007 25 5 909 920 2-s2.0-34147127615 10.1097/HJH.0b013e328048d004 (Pubitemid 46573105)
27. Lee Z. S. K., Critchley J. A. J. H., Tomlinson B., Young R. P., Thomas G. N., Cockram C. S., Chan T. Y. K., Chan J. C. N., Urinary epinephrine and norepinephrine interrelations with obesity, insulin, and the metabolic syndrome in Hong Kong Chinese. Metabolism 2001 50 2 135 143 2-s2.0-0035118204 10.1053/meta.2001.19502 (Pubitemid 32170823)
28. Kishi T., Hirooka Y., Konno S., Sunagawa K., Angiotensin II receptor blockers improve endothelial dysfunction associated with sympathetic hyperactivity in metabolic syndrome. Journal of Hypertension 2012 30 1646 1655
29. Smith M. M., Minson C. T., Obesity and adipokines: effect on sympathetic overactivity. The Journal of Physiology 2012 590 1787 1801
30. Lambert E., Sari C. I., Dawood T., Nguyen J., McGrane M., Eikelis N., Chopra R., Wong C., Chatzivlastou K., Head G., Straznicky N., Esler M., Schlaich M., Lambert G., Sympathetic nervous system activity is associated with obesity-induced subclinical organ damage in young adults. Hypertension 2010 56 3 351 358 2-s2.0-77955983169 10.1161/HYPERTENSIONAHA.110.155663
31. Rumantir M. S., Vaz M., Jennings G. L., Neural mechanisms in human obesity-related hypertension. Journal of Hypertension 1999 17 1125 1133 (Pubitemid 29389560)
32. Alvarez G. E., Ballard T. P., Beske S. D., Davy K. P., Subcutaneous obesity is not associated with sympathetic neural activation. American Journal of Physiology 2004 287 1 H414 H418 2-s2.0-1942517065 10.1152/ajpheart.01046.2003 (Pubitemid 38802379)
33. Huggett R. J., Burns J., Mackintosh A. F., Mary D. A., Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension 2004 44 6 847 852 2-s2.0-9644281403 10.1161/01.HYP.0000147893.08533.d8 (Pubitemid 39577410)
34. Sivitz W. I., Wayson S. M., Bayless M. L., Sinkey C. A., Haynes W. G., Obesity impairs vascular relaxation in human subjects: hyperglycemia exaggerates adrenergic vasoconstriction. Arterial dysfunction in obesity and diabetes. Journal of Diabetes and Its Complications 2007 21 3 149 157 2-s2.0-34247586046 10.1016/j.jdiacomp.2005.12.003 (Pubitemid 46687066)
35. Landsberg L., Insulin resistance, energy balance andsympathetic nervous system activity. Clinical and Experimental Hypertension 1990 12 817 830 (Pubitemid 20233516)
36. Landsberg L., Young J. B., Sympathoadrenal activity andobesity: physiological rationale for the use of adrenergicthermogenic drugs. International Journal of Obesity and Related Metabolic Disorders 1993 17 supplement 1 S29 S34 (Pubitemid 23092812)
37. Dulloo A. G., A sympathetic defense against obesity. Science 2002 297 5582 780 781 2-s2.0-0037008480 10.1126/science.1074923 (Pubitemid 34839615)
38. Young C. N., Deo S. H., Chaudhary K., Thyfault J. P., Fadel P. J., Insulin enhances the gain of arterial baroreflex control of muscle sympathetic nerve activity in humans. The Journal of Physiology 2010 588 18 3593 3603 2-s2.0-77956765040 10.1113/jphysiol.2010.191866
39. Muntzel M. S., Morgan D. A., Mark A. L., Johnson A. K., Intracerebroventricular insulin produces nonuniform regional increases in sympathetic nerve activity. American Journal of Physiology 1994 267 5 R1350 R1355 2-s2.0-0027953187
40. Rahmouni K., Morgan D. A., Morgan G. M., Liu X., Sigmund C. D., Mark A. L., Haynes W. G., Hypothalamic PI3K and MAPK differentially mediate regional sympathetic activation to insulin. The Journal of Clinical Investigation 2004 114 5 652 658 2-s2.0-4944242873 10.1172/JCI200421737 (Pubitemid 39578755)
41. Cassaglia P. A., Hermes S. M., Aicher S. A., Brooks V. L., Insulin acts in the arcuate nucleus to increase lumbar sympathetic nerve activity and baroreflex function in rats. The Journal of Physiology 2011 589 7 1643 1662 2-s2.0-79953156262 10.1113/jphysiol.2011.205575
42. Hopkins D. F., Williams G., Insulin receptors arewidely distributed in human brain and bind human andporcine insulin with equal affinity. Diabetic Medicine 1997 14 1044 1050 (Pubitemid 28015389)
43. Ciofi P., The arcuate nucleus as a circumventricular organ in the mouse. Neuroscience Letters 2011 487 2 187 190 2-s2.0-78650199265 10.1016/j.neulet. 2010.10.019
44. Dampney R. A., Arcuate nucleus-a gateway for insulin'saction on sympathetic activity. The Journal of Physiology 2011 589 2109 2110
45. Hilzendeger A. M., Morgan D. A., Brooks L., A brain leptin-renin angiotensin system interaction in the regulation of sympathetic nerve activity. American Journal of Physiology 2012 303 H197 H206
46. Harlan S. M., Morgan D. A., Agassandian K., Guo D. F., Cassell M. D., Sigmund C. D., Mark A. L., Rahmouni K., Ablation of the leptin receptor in the hypothalamic arcuate nucleus abrogates leptin-induced sympathetic activation. Circulation Research 2011 108 7 808 812 2-s2.0-79954701326 10.1161/CIRCRESAHA. 111.240226
47. Nagae A., Fujita M., Kawarazaki H., Matsui H., Ando K., Fujita T., Sympathoexcitation by oxidative stress in the brain mediates arterial pressure elevation in obesity-induced hypertension. Circulation 2009 119 7 978 986 2-s2.0-61849153939 10.1161/CIRCULATIONAHA.108.824730
48. Kishi T., Hirooka Y., Ogawa K., Konno S., Sunagawa K., Calorie restriction inhibits sympathetic nerve activity via anti-oxidant effect in the rostral ventrolateral medulla of obesity-induced hypertensive rats. Clinical and Experimental Hypertension 2011 33 4 240 245 2-s2.0-79959638287 10.3109/10641963.2011.583969
49. Dampney R. A. L., Functional organization of central pathways regulating the cardiovascular system. Physiological Reviews 1994 74 2 323 364 2-s2.0-0028258843 (Pubitemid 24127645)
50. Guyenet P. G., The sympathetic control of blood pressure. Nature Reviews Neuroscience 2006 7 5 335 346 2-s2.0-33745712914 10.1038/nrn1902
51. Kishi T., Hirooka Y., Kimura Y., Ito K., Shimokawa H., Takeshita A., Increased reactive oxygen species in rostral ventrolateral medulla contribute to neural mechanisms of hypertension in stroke-prone spontaneously hypertensive rats. Circulation 2004 109 19 2357 2362 2-s2.0-2442706556 10.1161/01.CIR. 0000128695.49900.12 (Pubitemid 38656873)
52. Stocker S. D., Meador R., Adams J. M., Neurons of the rostral ventrolateral medulla contribute to obesity-induced hypertension in rats. Hypertension 2007 49 3 640 646 2-s2.0-33847077261 10.1161/01.HYP.0000254828. 71253.dc
53. Dobrian A. D., Davies M. J., Schriver S. D., Lauterio T. J., Prewitt R. L., Oxidative stress in a rat model of obesity-induced hypertension. Hypertension 2001 37 2 554 560 2-s2.0-0035090072 (Pubitemid 32199027)
54. Smith A. D., Brands M. W., Wang M. H., Dorrance A. M., Obesity-induced hypertension develops in young rats independently of the renin-angiotensin- aldosterone system. Experimental Biology and Medicine 2006 231 3 282 287 2-s2.0-33644691034 (Pubitemid 43334313)
55. Dandona P., Aljada A., Chaudhuri A., Mohanty P., Garg R., Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005 111 11 1448 1454 2-s2.0-15444366991 10.1161/01.CIR.0000158483.13093.9D (Pubitemid 40396812)
56. Zhang X., Dong F., Ren J., Driscoll M. J., Culver B., High dietary fat induces NADPH oxidase-associated oxidative stress and inflammation in rat cerebral cortex. Experimental Neurology 2005 191 2 318 325 2-s2.0-11844263385 10.1016/j.expneurol.2004.10.011 (Pubitemid 40092875)
57. Boustany C. M., Bharadwaj K., Daugherty A., Brown D. R., Randall D. C., Cassis L. A., Activation of the systemic and adipose renin-angiotensin system in rats with diet-induced obesity and hypertension. American Journal of Physiology 2004 287 4 R943 R949 2-s2.0-4644307190 10.1152/ajpregu.00265.2004 (Pubitemid 39280483)
58. Giani J. F., Mayer M. A., Muñoz M. C., Silberman E. A., Höcht C., Taira C. A., Gironacci M. M., Turyn D., Dominici F. P., Chronic infusion of angiotensin-(1-7) improves insulin resistance and hypertension induced by a high-fructose diet in rats. American Journal of Physiology 2009 296 2 E262 E271 2-s2.0-60849095515 10.1152/ajpendo.90678.2008
59. Santos S. H., Braga J. F., Mario E. G., Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7). Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 953 961
60. Liu C., Lv X. H., Li H. X., Angiotensin-(1-7) suppresses oxidative stress and improves glucose uptake via Max receptor in adipocytes. Acta Diabetologica 2011 49 291 299
61. Padia S. H., Kemp B. A., Howell N. L., Gildea J. J., Keller S. R., Carey R. M., Intrarenal angiotensin III infusion induces natriuresis and angiotensin type 2 receptor translocation in Wistar-Kyoto but not in spontaneously hypertensive rats. Hypertension 2009 53 2 338 343 2-s2.0-59849116222 10.1161/HYPERTENSIONAHA.108.124198
62. Bourassa E. A., Fang X., Li X., Sved A. F., Speth R. C., AT1 angiotensin II receptor and novel non-AT1, non-AT2 angiotensin II/III binding site in brainstem cardiovascular regulatory centers of the spontaneously hypertensive rat. Brain Research 2010 1359 98 106 2-s2.0-77958005097 10.1016/j.brainres.2010. 08.081
63. Nickenig G., Sachinidis A., Michaelsen F., Böhm M., Seewald S., Vetter H., Upregulation of vascular angiotensin II receptor gene expression by low- density lipoprotein in vascular smooth muscle cells. Circulation 1997 95 2 473 478 2-s2.0-0031023734 (Pubitemid 27056216)
64. Nickenig G., Jung O., Strehlow K., Zolk O., Linz W., Schölkens B. A., Böhm M., Hypercholesterolemia is associated with enhanced angiotensin AT1- receptor expression. American Journal of Physiology 1997 272 6 H2701 H2707 2-s2.0-0030872917
65. Daugherty A., Rateri D. L., Lu H., Inagami T., Cassis L. A., Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 2004 110 25 3849 3857 2-s2.0-11144328072 10.1161/01.CIR.0000150540.54220.C4 (Pubitemid 40023984)
66. Mateos L., Ismail M. A. M., Gil-Bea F. J., Schüle R., Schöls L., Heverin M., Folkesson R., Björkhem I., Cedazo-Mínguez A., Side chain-oxidized oxysterols regulate the brain renin-angiotensin system through a liver X receptor-dependent mechanism. The Journal of Biological Chemistry 2011 286 29 25574 25585 2-s2.0-79960400007 10.1074/jbc.M111.236877
67. Zhang S. L., Filep J. G., Hohman T. C., Tang S. S., Ingelfinger J. R., Chan J. S. D., Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells. Kidney International 1999 55 2 454 464 2-s2.0-0032913340 10.1046/j.1523-1755.1999.00271.x (Pubitemid 29082872)
68. Siragy H. M., Huang J., Renal (pro)renin receptor upregulation in diabetic rats through enhanced angiotensin AT1 receptor and NADPH oxidase activity. Experimental Physiology 2008 93 5 709 714 2-s2.0-42649140868 10.1113/expphysiol.2007.040550 (Pubitemid 351595048)
69. Toma I., Kang J. J., Sipos A., Vargas S., Bansal E., Hanner F., Meer E., Peti-Peterdi J., Succinate receptor GPR91 provides a direct link between high glucose levels and rennin release in murine and rabbit kidney. The Journal of Clinical Investigation 2008 118 7 2526 2534 2-s2.0-46749087465 10.1172/JC133293 (Pubitemid 351949780)
70. Zhou L., Xue H., Yuan P., Ni J., Yu C., Huang Y., Lu L. M., Angiotensin AT1 receptor activation mediates high glucose-induced epithelial-mesenchymal transition in renal proximal tubular cells. Clinical and Experimental Pharmacology and Physiology 2010 37 9 e152 e157 2-s2.0-77956048706 10.1111/j.1440-1681.2010.05421.x
71. Richey J. M., Ader M., Moore D., Bergman R. N., Angiotensin II induces insulin resistance independent of changes in interstitial insulin. American Journal of Physiology 1999 277 5 E920 E926 2-s2.0-0032760296
72. Ogihara T., Asano T., Ando K., Chiba Y., Sakoda H., Anai M., Shojima N., Ono H., Onishi Y., Fujishiro M., Katagiri H., Fukushima Y., Kikuchi M., Noguchi N., Aburatani H., Komuro I., Fujita T., Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002 40 6 872 879 2-s2.0-0036899150 10.1161/01.HYP.0000040262.48405.A8 (Pubitemid 35434909)
73. Sloniger J. A., Saengsirisuwan V., Diehl C. J., Dokken B. B., Lailerd N., Lemieux A. M., Kim J. S., Henriksen E. J., Defective insulin signaling in skeletal muscle of the hypertensive TG(mREN2)27 rat. American Journal of Physiology 2005 288 6 E1074 E1081 2-s2.0-19444379931 10.1152/ajpendo.00396.2004 (Pubitemid 40726793)
74. Kouyama R., Suganami T., Nishida J., Tanaka M., Toyoda T., Kiso M., Chiwata T., Miyamoto Y., Yoshimasa Y., Fukamizu A., Horiuchi M., Hirata Y., Ogawa Y., Attenuation of diet-induced weight gain and adiposity through increased energy expenditure in mice lacking angiotensin II type 1a receptor. Endocrinology 2005 146 8 3481 3489 2-s2.0-23044505229 10.1210/en.2005-0003 (Pubitemid 41065022)
75. Pscherer S., Heemann U., Frank H., Effect of renin-angiotensin system blockade on insulin resistance and inflammatory parameters in patients with impaired glucose tolerance. Diabetes Care 2010 33 4 914 919 2-s2.0-77953034623 10.2337/dc09-1381
76. Yusuf S., Gerstein H., Hoogwerf B., Pogue J., Bosch J., Wolffenbuttel B. H. R., Zinman B., Ramipril and the development of diabetes. Journal of the American Medical Association 2001 286 15 1882 1885 2-s2.0-0035904369 (Pubitemid 33010241)
77. Barzilay J. I., Davis B. R., Cutler J. A., Pressel S. L., Whelton P. K., Basile J., Margolis K. L., Ong S. T., Sadler L. S., Summerson J., Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Archives of Internal Medicine 2006 166 20 2191 2201 2-s2.0-33750999057 10.1001/archinte.166.20.2191 (Pubitemid 44748765)
78. Bosch J., Yusuf S., Gerstein H. C., Effect of ramipril on the incidence of diabetes. The New England Journal of Medicine 2006 355 1551 1562 (Pubitemid 44550032)
79. McMurray J. J., Holman R. R., Haffner S. M., Effect of valsartan on the incidence of diabetes andcardiovascular events. The New England Journal of Medicine 2010 362 1477 1490
80. Grassi G., Seravalle G., Dell'Oro R., Trevano F. Q., Bombelli M., Scopelliti F., Facchini A., Mancia G., Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. Journal of Hypertension 2003 21 9 1761 1769 2-s2.0-0041885190 10.1097/00004872-200309000- 00027 (Pubitemid 37076361)
81. Gao X. Y., Zhang F., Han Y., Wang H. J., Zhang Y., Guo R., Zhu G. Q., AT1 receptor in rostral ventrolateral medulla mediating blunted baroreceptor reflex in spontaneously hypertensive rats. Acta Pharmacologica Sinica 2004 25 11 1433 1438 2-s2.0-8544273684 (Pubitemid 39490887)
82. Koga Y., Hirooka Y., Araki S., Nozoe M., Kishi T., Sunagawa K., High salt intake enhances blood pressure increase during development of hypertension via oxidative stress in rostral ventrolateral medulla of spontaneously hypertensive rats. Hypertension Research 2008 31 11 2075 2083 2-s2.0-58849118857 10.1291/hypres.31.2075
83. Ito S., Komatsu K., Tsukamoto K., Kanmatsuse K., Sved A. F., Ventrolateral medulla AT1 receptors support blood pressure in hypertensive rats. Hypertension 2002 40 4 552 559 2-s2.0-0036771845 10.1161/01.HYP.0000033812. 99089.92
84. Gohlke P., Weiss S., Jansen A., Wienen W., Stangier J., Rascher W., Culman J., Unger T., AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. Journal of Pharmacology and Experimental Therapeutics 2001 298 1 62 70 2-s2.0-0034743612 (Pubitemid 32574511)
85. Wang J. M., Tan J., Leenen F. H. H., Central nervous system blockade by peripheral administration of AT1 receptor blockers. Journal of Cardiovascular Pharmacology 2003 41 4 593 599 2-s2.0-0037380939 10.1097/00005344-200304000- 00012 (Pubitemid 36373797)
86. Lin Y., Matsumura K., Kagiyama S., Fukuhara M., Fujii K., Iida M., Chronic administration of olmesartan attenuates the exaggerated pressor response to glutamate in the rostral ventrolateral medulla of SHR. Brain Research 2005 1058 1-2 161 166 2-s2.0-26244453700 10.1016/j.brainres.2005.07.070 (Pubitemid 41416810)
87. Lin Y., Tsuchihashi T., Kagiyama S., Matsumura K., Abe I., The influence of chronic antihypertensive treatment on the central pressor response in SHR. Hypertension Research 2001 24 2 173 178 2-s2.0-0035032039 10.1291/hypres.24.173 (Pubitemid 32377589)
88. Tsuchihashi T., Kagiyama S., Matsumura K., Abe I., Fujishima M., Effects of chronic oral treatment with imidapril and TCV-116 on the responsiveness to angiotensin II in ventrolateral medulla of SHR. Journal of Hypertension 1999 17 7 917 922 2-s2.0-0033024799 10.1097/00004872-199917070-00007 (Pubitemid 29322179)
89. Pelisch N., Hosomi N., Ueno M., Masugata H., Murao K., Hitomi H., Nakano D., Kobori H., Nishiyama A., Kohno M., Systemic candesartan reduces brain angiotensin II via downregulation of brain renin-angiotensin system. Hypertension Research 2010 33 2 161 164 2-s2.0-76349103242 10.1038/hr.2009.200
90. Schupp M., Janke J., Clasen R., Unger T., Kintscher U., Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004 109 17 2054 2057 2-s2.0-2442451618 10.1161/01.CIR.0000127955.36250.65 (Pubitemid 38620211)
91. Benson S. C., Pershadsingh H. A., Ho C. I., Chittiboyina A., Desai P., Pravenec M., Qi N., Wang J., Avery M. A., Kurtz T. W., Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004 43 5 993 1002 2-s2.0-1542547460 10.1161/01.HYP.0000123072.34629.57 (Pubitemid 38579904)